Pfizer leads Big Pharma's emerging markets growth as GlaxoSmithKline, Eli Lilly lag

19th September 2017 Uncategorised 0

Big Pharma expanded in emerging markets 6.1% last quarter, the biggest jump in more than two years, but GlaxoSmithKline and Eli Lilly didn’t reap as much growth as their peers—and all of them may face rising threats ahead.

More: Pfizer leads Big Pharma's emerging markets growth as GlaxoSmithKline, Eli Lilly lag
Source: fierce